Draft:Gene Solutions
Biotechnology company headquartered in Singapore
From Wikipedia, the free encyclopedia
Gene Solutions is a biotechnology company founded in Vietnam, headquartered in Singapore. The company provides genetic testing services in reproductive health and oncology, including noninvasive prenatal testing (NIPT), multicancer early detection (MCED), molecular residual disease (MRD) monitoring, and comprehensive genomic profiling (CGP).[1][2]
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 2,917 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 22 December 2025 by WeWake (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
| Submission declined on 21 July 2025 by Pythoncoder (talk). This draft appears to be generated by a large language model (such as ChatGPT). You should not use LLMs to write articles from scratch.
Declined by Pythoncoder 7 months ago.LLM-generated pages with the below issues may be deleted without notice. These tools are prone to specific issues that violate our policies:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. | |
| Company type | Private |
|---|---|
| Industry | Genetic testing |
| Founded | 2017 |
| Founders | Nguyễn Hoài Nghĩa, Giang Hoa, Nguyễn Hữu Nguyên |
| Headquarters | Singapore |
Area served | Asia-Pacific, Americas, Europe |
| Website | https://genesolutions.com |
Gene Solutions operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) and ISO 15189 in Singapore and Ho Chi Minh City, Vietnam.[3][4]
History
Gene Solutions was founded in 2017 by Nguyễn Hoài Nghĩa, Giang Hoa, and Nguyễn Hữu Nguyên.[5][6]
In 2018, Gene Solutions launched its first Noninvasive prenatal testing (NIPT), triSure, initially focusing on reproductive genetics in Vietnam.
In April 2022, Gene Solutions expanded into oncology with the introduction of SPOT-MAS, a liquid biopsy workflow for multi-cancer early detection.[7][8]
In 2022, Gene Solutions launched K-TRACK, a circulating tumor DNA (ctDNA) test for molecular residual disease monitoring. In September 2023, Gene Solutions released K-4CARE, a comprehensive genomic and transcriptomic profiling test for therapy selection.[9]
As of January 2026[update], Gene Solutions has processed over 3 million cell-free DNA tests. Its proprietary technology has been documented in over 50 peer reviewed publications[10][11][12][13][14][15][16][17][18][19] including Nature, Science (journal), European Society for Medical Oncology (ESMO) Journals, ...
Operations
Funding
In 2021, Gene Solutions received a $15 million investment from Mekong Capital's Mekong Enterprise Fund IV,[23][24][25] followed by a $21 million Series B round from the same investor in 2023.[26][27]
In 2025, Gene Solutions received an investment of an undisclosed amount from the Singapore-based healthcare firm August Global Partners to support regional expansion and technology development.[28][29][30][31]
In November 2025, Gene Solutions announced plans to raise $100 million through a pre-IPO funding round and a subsequent public listing scheduled for 2026.[32][33][34]
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.